These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27537326)

  • 41. Channeling and prevalence of cardiovascular contraindications in users of cyclooxygenase 2 selective nonsteroidal antiinflammatory drugs.
    Mosis G; Stijnen T; Castellsague J; Dieleman JP; van der Lei J; Stricker BH; Sturkenboom MC
    Arthritis Rheum; 2006 Aug; 55(4):537-42. PubMed ID: 16874797
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs and Classical and Selective Cyclooxygenase-2 Inhibitors: A Meta-analysis of Observational Studies.
    Martín Arias LH; Martín González A; Sanz Fadrique R; Vazquez ES
    J Clin Pharmacol; 2019 Jan; 59(1):55-73. PubMed ID: 30204233
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritis.
    Lee C; Hunsche E; Balshaw R; Kong SX; Schnitzer TJ
    Arthritis Rheum; 2005 Aug; 53(4):510-8. PubMed ID: 16082648
    [TBL] [Abstract][Full Text] [Related]  

  • 45. COX-2-selective inhibitors (COXIBs): gastrointestinal safety.
    Pronai L; Hritz I; Molnar B; Herszenyi L; Tulassay Z
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):23-30. PubMed ID: 14552701
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The safety of COX-2 inhibitors].
    Lakatos G; Herszényi L; Tulassay Z
    Orv Hetil; 2008 Aug; 149(33):1539-47. PubMed ID: 18687572
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The coxibs and traditional nonsteroidal anti-inflammatory drugs: a current perspective on cardiovascular risks.
    Cairns JA
    Can J Cardiol; 2007 Feb; 23(2):125-31. PubMed ID: 17311118
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Coxib's Safety in Patients with Inflammatory Bowel Diseases: A Meta-analysis.
    Ribaldone DG; Fagoonee S; Astegiano M; De Angelis C; Smedile A; Caviglia GP; Petrini E; Greco A; Pellicano R
    Pain Physician; 2015 Nov; 18(6):599-607. PubMed ID: 26606012
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Introduction - The coxib controversies.
    Rainsford KD
    Inflammopharmacology; 2005; 13(4):331-41. PubMed ID: 16354388
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
    De Vecchis R; Baldi C; Di Biase G; Ariano C; Cioppa C; Giasi A; Valente L; Cantatrione S
    Minerva Cardioangiol; 2014 Dec; 62(6):437-48. PubMed ID: 25029569
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nonsteroidal antiinflammatory drugs: past, present and future.
    Patrono C; Rocca B
    Pharmacol Res; 2009 May; 59(5):285-9. PubMed ID: 19416627
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors of the selection of coxibs over nonselective NSAIDs in an older Medicaid cohort.
    Shireman TI; Rigler SK
    Am J Geriatr Pharmacother; 2006 Sep; 4(3):210-8. PubMed ID: 17062321
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.
    Moore RA; Derry S; Phillips CJ; McQuay HJ
    BMC Musculoskelet Disord; 2006 Oct; 7():79. PubMed ID: 17054784
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The comparative safety of analgesics in older adults with arthritis.
    Solomon DH; Rassen JA; Glynn RJ; Lee J; Levin R; Schneeweiss S
    Arch Intern Med; 2010 Dec; 170(22):1968-76. PubMed ID: 21149752
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Management of Adverse Effects Associated with Nonsteroidal Anti-inflammatory Drugs and COX-2 Inhibitor].
    Masuda R
    Masui; 2016 Aug; 65(7):709-717. PubMed ID: 30358302
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cyclooxygenase-2 inhibitors: what went wrong?
    James MJ; Cleland LG
    Curr Opin Clin Nutr Metab Care; 2006 Mar; 9(2):89-94. PubMed ID: 16477171
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke.
    Roumie CL; Mitchel EF; Kaltenbach L; Arbogast PG; Gideon P; Griffin MR
    Stroke; 2008 Jul; 39(7):2037-45. PubMed ID: 18436878
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.
    Tannenbaum H; Bombardier C; Davis P; Russell AS;
    J Rheumatol; 2006 Jan; 33(1):140-57. PubMed ID: 16331802
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Exercise-associated hyponatremia, renal function, and nonsteroidal antiinflammatory drug use in an ultraendurance mountain run.
    Page AJ; Reid SA; Speedy DB; Mulligan GP; Thompson J
    Clin J Sport Med; 2007 Jan; 17(1):43-8. PubMed ID: 17304005
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges.
    Patrono C; Baigent C
    Mol Interv; 2009 Feb; 9(1):31-9. PubMed ID: 19299662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.